A long and fruitful partnership in the world of cancer research began in 2006 in Hollywood with AACR CEO Margaret Foti, PhD, MD (hc), attending a meeting with Sherry Lansing, former chairman and CEO...
Radiation therapy is falling out of favor for some cancer types, and concerns grow about commercially available multi-cancer detection tests.
Lorazepam used to relieve stress may cause inflammation that promotes tumor growth and shortens progression-free survival, study says. A medication commonly used to ease the stress caused by cancer diagnosis and treatment may be...
The FDA approved a kit that allows for liver-directed delivery of the chemotherapy melphalan to treat metastatic liver disease from uveal melanoma. The U.S. Food and Drug Administration (FDA) has approved a kit for...
Black men with melanoma are more likely than other populations to die of the disease. Here’s why, and what to look for.
The FDA has approved another T-cell engager therapy for patients with heavily pretreated multiple myeloma The U.S. Food and Drug Administration (FDA) has granted accelerated approval to elranatamab-bcmm (Elrexfio) for the treatment of adult...
The FDA approved a combination of the PARP inhibitor niraparib with a hormone therapy agent for certain patients with metastatic prostate cancer The U.S. Food and Drug Administration (FDA) has approved the combination of...
Research links testicular cancer in military firefighters to ‘forever chemicals,’ and older women who are screened for breast cancer at risk for overdiagnosis.
The FDA granted full approval to pralsetinib as a treatment for certain patients with non-small cell lung cancer The U.S. Food and Drug Administration has granted full approval to pralsetinib (Gavreto) to treat adult...
Certain patients with advanced multiple myeloma may be eligible for treatment with a new immunotherapy drug. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to talquetamab-tgvs (Talvey) for patients with multiple...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More